GLTO Stock Overview
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.
+ 1 more risk
Galecto, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.94|
|52 Week High||US$3.92|
|52 Week Low||US$1.17|
|1 Month Change||-22.71%|
|3 Month Change||7.78%|
|1 Year Change||-48.68%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-87.07%|
Recent News & Updates
Galecto GAAP EPS of -$0.67 beats by $0.02
Galecto press release (NASDAQ:GLTO): Q2 GAAP EPS of -$0.67 beats by $0.02. Cash, cash equivalents, and investments as of June 30, 2022 were approximately $85.9 million.
We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|GLTO||US Biotechs||US Market|
Return vs Industry: GLTO underperformed the US Biotechs industry which returned -30% over the past year.
Return vs Market: GLTO underperformed the US Market which returned -23% over the past year.
|GLTO Average Weekly Movement||11.2%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: GLTO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: GLTO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Galecto, Inc. Fundamentals Summary
|GLTO fundamental statistics|
Is GLTO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GLTO income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.36|
|Net Profit Margin||0.00%|
How did GLTO perform over the long term?See historical performance and comparison